{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001909","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.104529+00:00","generated_at":"2026-05-16T10:38:54.031925+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Castle Biosciences expects 2025 revenue >$340M, above guidance; core test volumes up 37% YoY","bullets":["2025 total revenue >$340M, above guided range of $327-335M.","Q4 core test reports (DecisionDx-Melanoma, TissueCypher) +42% YoY.","DecisionDx-Melanoma Q4: 10,022 reports; TissueCypher Q4: 11,803 reports.","Year-end cash + marketable securities ~$300M.","AdvanceAD-Tx launched Nov 2025; >50% of initial clinicians ordered in first 5 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001909","json":"https://secwatch.observer/filing/0001628280-26-001909.json","markdown":"https://secwatch.observer/filing/0001628280-26-001909.md","text":"https://secwatch.observer/filing/0001628280-26-001909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000162828026001909/0001628280-26-001909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000162828026001909/cstl-20260111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:38:54.031925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}